This page shows the latest irritable bowel syndrome news and features for those working in and with pharma, biotech and healthcare.
Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic constipation as well as constipation linked to irritable bowel syndrome and chronic opioid
NICE has recommended routine NHS funding for Allergan's Truberzi, which is the first drug for irritable bowel syndrome with diarrhoea (IBS-D) to pass through its review process.
In trials, a once-daily dose of Trulance was more effective than placebo to improve the frequency of bowel movements in patients diagnosed with CIC for at least six months. ... constipation linked to irritable bowel syndrome (IBS).
Now, the Canadian company has decided to build up Salix' salesforce to push its flagship brand – Xifaxan (rifaximin) for diarrhoea caused by irritable bowel syndrome – which has been tipped by some
Other positive recommendations were given for Aptalis' Truberzi (eluxadoline) as a treatment for irritable bowel syndrome with diarrhoea, along with two biosimilar versions of Sanofi's clot-busting drug Lovenox (enoxaparin) -
Ferring Pharmaceuticals has signed a telemedicine deal with a Copenhagen hospital that it hopes will transform patient care in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
More from news
Approximately 1 fully matching, plus 50 partially matching documents found.
An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... This campaign showed doctors suffering from Irritable Disbelief Syndrome (IDS) - a brave move but exactly the perception shift
His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation. ... ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
She is convinced that biosimilars are essential in treating patients with chronic conditions such as rheumatoid arthritis, irritable bowel syndrome and psoriasis, because they provide the same uplift in quality of
years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... Among these are Avaxia Biologics, which
associated with nephrotic syndrome, certain rheumatology-related conditions, and infantile spasms. ... Eluxadoline is a first-in-class, locally-acting mu opioid receptor agonist/ delta opioid receptor antagonist for treating symptoms of
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
irritable bowel syndrome and constipation. “
Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe, where the drug is marketed as Constella by Almirall.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...